



**HAL**  
open science

## Reference Method and Reference Material Are Necessary Tools to Reveal the Variability of Cystatin C Assays

Anne-Sophie Bargnoux, Nils Kuster, Vincent Delatour, Pierre Delanaye, Ana González-Antuña, Jean-Paul Cristol, Laurence Piéroni, Etienne Cavalier

► **To cite this version:**

Anne-Sophie Bargnoux, Nils Kuster, Vincent Delatour, Pierre Delanaye, Ana González-Antuña, et al.. Reference Method and Reference Material Are Necessary Tools to Reveal the Variability of Cystatin C Assays. *Archives of Pathology and Laboratory Medicine*, 2016, 140 (2), pp.117 - 118. 10.5858/arpa.2015-0198-LE . hal-01803383

**HAL Id: hal-01803383**

**<https://hal.umontpellier.fr/hal-01803383>**


Submitted on 3 Dec 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Reference Method and Reference Material Are Necessary Tools to Reveal the Variability of Cystatin C Assays

*To the Editor.*—We read with great interest the article by Eckfeldt et al<sup>1</sup> regarding the accuracy of cystatin C (cystC) measurements in the College of American Pathologists 2014 survey. In 2008, The French Society of Clinical Biology (SFBC) conducted a multicentric evaluation of isotope dilution mass spectrometry (IDMS)-traceable creatinine enzymatic and nonstandardized cystC assays<sup>2</sup> using a panel of 5 off-the-clot, fresh-frozen serum pools prepared to cover concentrations critically important at initial stages of renal disease. Nine automated methods were evaluated: 4 particle-enhanced nephelometry immunoassay: Siemens on BN II, ProSpec, and Vista (Siemens Healthcare Diagnostics, Marburg, Germany), and Dako reagents (DakoCytomation, Glostrup, Denmark) on Beckman Image (Beckman Coulter, Fullerton, California); and 5 particle-enhanced turbidimetry immunoassays: Thermo Fisher on KoneLab (Thermo Fisher Scientific, Passau, Germany), Dako reagents on ARCHITECT (Abbott Laboratories, Abbott Park, Illinois), Dako reagents on Olympus AU2700 (Olympus, Rungis, France), Gentian (Gentian, Moss, Norway) reagents on ARCHITECT, and Roche Tina-quant on Modular analyzer (Roche Diagnostics, Mannheim, Germany). Each method (reagent/analyzer) was assessed independently by 3 different laboratories. The pools were assayed on 3 separate runs per day for 3 consecutive days.<sup>2</sup> At that time, there was no reference method, and no certified reference material was available,<sup>3</sup> making it difficult to assign reference values to our samples. To overcome that issue, an IDMS-based candidate-reference method from the University of Oviedo (Oviedo, Spain) had its accuracy successfully validated with the recently released certified reference material ERM-DA471/IFCC (International Federation of Clinical Chemistry and Laboratory).<sup>4</sup> The IDMS cystC mean (SD) levels, measured in pools stored at  $-80^{\circ}\text{C}$ , were 0.703 (0.056), 0.806 (0.073), 0.905 (0.046), 1.282 (0.057),



Monte-Carlo simulations representing 95% confidence regions of performances (relative deviation against isotope dilution mass spectrometry [IDMS] and imprecision value couples) for pool 1 (A), pool 2 (B), pool 3 (C), pool 4 (D), and pool 5 (E) sorted by cystatin C (cystC) reagent-analyzer combinations. Nine automated CystC reagent-analyzer combinations were evaluated: Thermo Fisher on KoneLab (Thermo Fisher Scientific); Siemens on BN II, ProSpec, Vista (Siemens Healthcare Diagnostics); Dako reagents (DakoCytomation) on ARCHITECT (Abbott Laboratories), Beckman Image (Beckman Coulter), and Olympus AU2700 (Olympus), Gentian (Gentian) reagents on ARCHITECT and Roche Tina-quant on Modular (Roche Diagnostics). Continuous curve, region defined by a total error less than 7.6%. Dashed curve, region defined by a total error less than 11.4%.

and 1.476 (0.063) mg/L for pools 1, 2, 3, 4, and 5, respectively. Because the design of the College of American Pathologists study and our study were similar, we decided to compare our findings to those subsequently obtained by Eckfeldt et al<sup>1</sup> using ERM-DA471/IFCC traceable target values.

The performance of the assays (total error includes the contribution of bias and imprecision) were computed using Monte-Carlo simulations and compared against Ricos criteria based

on both intraindividual (5%) and the interindividual (13%) biologic variation of cystC. The combination of bias and precision (standard deviation) delimiting the desirable (total error = 7.6%) and minimum (total error = 11.4%) performances were obtained and plotted as parabolic curves (Figure, A through E). We observed a high dispersion in cystC values with interlaboratory coefficients of variation ranging from 2% (pool 1, Gentian; mean [SD], 0.69 [0.01] mg/L) (Figure,

A) to 7% (pool 5, Thermo; mean [SD], 1.64 [0.11] mg/L) (Figure, E). In total agreement with the College of American Pathologists reports, the Siemens methods exhibited a negative bias ranging from -11% (pool 3, BNII; bias, -0.10 mg/L) (Figure, C) to -18% (pool 1, BN ProSpec; bias, -0.13 mg/L) (Figure, A) compared with the IDMS target value. The Gentian method exhibited the best accuracy with both the lowest bias (<4.1%, pool 5; bias, 0.06 mg/L) (Figure, E) and precision among laboratories (<3.5%, pool 3; mean [SD], 0.91 [0.03] mg/L) (Figure, C). By contrast, the Roche method displayed a positive bias, ranging from 7% (pool 5; bias, 0.10 mg/L) (Figure, E) to 16% (pool 1; bias, 0.11 mg/L) (Figure, A) in our study. In addition, we observed a positive bias, ranging from 11% (pool 2, Olympus; bias, 0.09 mg/L) (Figure, B) to 36% (pool 1, ARCHITECT; bias, 0.25 mg/L) (Figure, A) for the Dako reagents and from 5% (pool 2; bias, 0.04 mg/L) (Figure, B) to 11% (pool 5; bias, 0.16 mg/L) (Figure, E) for cystC Thermo/KoneLab.

The comparison between the two studies demonstrated that despite standardization of cystC assays, the variability of cystC measurements was similar when compared with ERM-DA471/IFCC traceable target values or IDMS reference methods. It is difficult to speculate on the causes of the between-method differences versus the IDMS method, which could be attributed to analytic factors, such as antibody selectivity, method adaptation with different instruments, incor-

rect assignment of calibrator values, or noncommutability of manufacturer's calibrators. For example, the Roche method showed an improvement between the two periods. The manufacturer claimed that the method had been standardized against ERM-DA471/IFCC reference material in 2014, whereas the first generation of Tina-quant CystC was standardized against an in-house gravimetric (dry mass) reference preparation of pure recombinant human cystC. More studies need to be performed to reliably use cystC in assessing kidney function alone or in combination with creatinine.<sup>5</sup> To check the effect of standardization of cystC methods, the SFBC group initiated a new study based on a similar experimental design as that in 2008. The primary available, standardized cystC methods are currently being compared versus IDMS-based candidate reference method using 5 commutable serum pools ranging from 0.9 to 2.2 mg/L.

Anne-Sophie Bargnoux, MD, PhD<sup>1</sup>; Nils Kuster, MD, PhD<sup>1</sup>; Vincent Delatour, PhD<sup>2</sup>; Pierre Delanaye, MD, PhD<sup>3</sup>; Ana González-Antuña, PhD<sup>4,5</sup>; Jean-Paul Cristol, MD, PhD<sup>1</sup>; Laurence Piéroni, MD, PhD<sup>6</sup>; Etienne Cavalier, MD, PhD<sup>5</sup>; on behalf of the Société Française de Biologie Clinique

<sup>1</sup> Laboratoire de Biochimie, CHRU de Montpellier, PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier, France; <sup>2</sup> Department of Biomedical and Organic Chemistry, Laboratoire National de

Métrie et d'Essais (LNE), Paris, France; <sup>3</sup> Department of Nephrology, Dialysis and Hypertension, University of Liege, CHU Sart-Tilman, Liege, Belgium; <sup>4</sup> Department of Physical and Analytical Chemistry, Faculty of Chemistry, University of Oviedo, Oviedo, Spain; <sup>5</sup> Department of Clinical Chemistry, University of Liege, CHU Sart-Tilman, Liege, Belgium; <sup>6</sup> Laboratoire de Biologie Médicale, Centre Hospitalier d'Avignon, Avignon, France

1. Eckfeldt JH, Karger AB, Miller WG, Rynders GP, Inker LA. Performance in measurement of serum cystatin C by laboratories participating in the College of American Pathologists 2014 CYS survey. *Arch Pathol Lab Med.* 2015;139(7):888-893. doi: 10.5858/arpa.2014-0427-CP.

2. Piéroni L, Delanaye P, Boutten A, et al; Société Française de Biologie Clinique (SFBC). A multicentric evaluation of IDMS-traceable creatinine enzymatic assays. *Clin Chim Acta.* 2011;412(23-24):2070-2075.

3. Grubb A, Blirup-Jensen S, Lindström V, Schmidt C, Althaus H, Zegers I; IFCC Working Group on Standardisation of Cystatin C (WG-SCC). First certified reference material for cystatin C in human serum ERM-DA471/IFCC. *Clin Chem Lab Med.* 2010;48(11):1619-1621.

4. González-Antuña A, Rodríguez-González P, Ohlendorf R, Henrion A, Delatour V, García Alonso JI. Determination of Cystatin C in human serum by isotope dilution mass spectrometry using mass overlapping peptides. *J Proteomics.* 2015;112:141-155.

5. Shlipak MG, Matsushita K, Ärnlöv J, et al; CKD Prognosis Consortium. Cystatin C versus creatinine in determining risk based on kidney function. *N Engl J Med.* 2013;369(10):932-943.

The authors have no relevant financial interest in the products or companies described in this article.